Flow Reactor Chip Improves Control of Highly Exothermic Reactions
Uniqsis Ltd has released an application note** that demonstrates how its proprietary glass static mixer-reactor chip technology can be used to perform highly exothermic reactions more conveniently at higher temperatures with better throughputs under continuous flow-through conditions.
To achieve high reproducibility and facilitate scale up, it is important to control both mixing and temperature, particularly for highly exothermic or rapid mixing-dependent reactions (‘Type A’ reactions).
Where the diffusional mixing provided by simple ‘T’-piece mixers is too slow to afford good control and reproducible reaction outcomes, Uniqsis has introduced a range of ingenious glass static mixer blocks ('chips') that incorporate channels with active mixing geometries to provide efficient turbulent mixing throughout the reaction vessel whilst also functioning as very efficient heat exchangers.
Uniqsis offers both conventional 2 input 1 output static glass mixer/reactor chips for combining 2 reagent streams, useful in nitration chemistry for example, and a 3 input 1 output chip which is particularly useful for reactions requiring a ‘quench’ input. The chips are easy to incorporate into the reaction flow path and use conventional threaded connectors that require no tools to attach and achieve leak-free seals over a wide temperature range. Precision machined from chemically inert borosilicate glass, these chip are tested to operate efficiently at up to 40 bar pressure and from -80 °C to +150 °C.
Metalations are typically performed at very low temperature (often -78 °C) in batch with slow addition of the organometallic base in order to control the highly exothermic nature of such reactions. In Application Note 25** - Uniqsis demonstrate how a low temperature metalation-quench reaction can be performed at higher temperature in flow using the mixer-reactor chip in combination with a FlowSyn Cold Coil is able to reproducibly perform a high yield metalation-quench reaction.
Uniqsis mixer-reactor chips in combination with a FlowSyn column module, Cold Coil or Polar Bear reaction station offer a convenient and reliable solution to the control of mixing and temperature in chemical synthesis. For further information about using the glass static mixer-reactor chip technology please contact Uniqsis now on +44 845 864 7747 or [email protected].
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance